Request Demo
Last update 20 Mar 2025
MEDI-0618
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms |
Target |
Action antagonists |
Mechanism PAR-2 antagonists(Protease-activated receptor-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with MEDI-0618CTIS2024-512904-21-00
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants with Episodic Migraine - D7060C00003
NCT06602479
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine
NCT05714254
A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers
100 Clinical Results associated with MEDI-0618
Login to view more data
100 Translational Medicine associated with MEDI-0618
Login to view more data
100 Patents (Medical) associated with MEDI-0618
Login to view more data
100 Deals associated with MEDI-0618
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Migraine Without Aura | Phase 2 | Poland | 07 Oct 2024 | |
| Migraine Without Aura | Phase 2 | Netherlands | 07 Oct 2024 | |
| Migraine Without Aura | Phase 2 | Spain | 07 Oct 2024 | |
| Migraine Without Aura | Phase 2 | Italy | 07 Oct 2024 | |
| Migraine Without Aura | Phase 2 | Czechia | 07 Oct 2024 | |
| Migraine Without Aura | Phase 2 | Germany | 07 Oct 2024 | |
| Migraine Without Aura | Phase 2 | Hungary | 07 Oct 2024 | |
| Migraine Without Aura | Phase 2 | United States | 07 Oct 2024 | |
| Migraine Without Aura | Phase 2 | Denmark | 07 Oct 2024 | |
| Migraine Disorders | Phase 1 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free